OnKure Therapeutics (OKUR) Non Operating Interest Expenses (2024 - 2025)
OnKure Therapeutics' (OKUR) quarterly Non Operating Interest Expenses came in at $6000.0 in Q4 2025, down 89.47% YoY from $57000.0 in Q4 2024, and up 200.0% on a QoQ basis from $2000.0 in Q3 2025.
OnKure Therapeutics (OKUR) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
OnKure Therapeutics (OKUR) has 2 years of Non Operating Interest Expenses data on file, last reported at $6000.0 in Q4 2025.
- Quarterly Non Operating Interest Expenses fell 89.47% year-over-year to $6000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $283000.0 (changed N/A YoY) and the FY2025 annual result came in at $8000.0, down 97.33% from the prior year.
- Non Operating Interest Expenses grew to $6000.0 in Q4 2025, from $2000.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $218000.0 in Q3 2024 to a low of $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 26,000.00 |